ArticleCureus2025
A Diagnostic Uncertainty in an Immunocompromised Patient: Rapidly Progressive Interstitial Lung Disease vs. Pneumocystis Pneumonia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathogen-Specific PET Imaging of Pulmonary Infection Using [Chemical & biomedical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic inflammatory myopathies (IIM) are a diverse group of autoimmune disorders characterized by muscle weakness and involvement of extra-muscular organs, including the skin and lungs. The occurrence of interstitial lung disease (ILD) is considered a poor prognostic factor. While antibodies such as anti-Jo-1 and anti-MDA5 are associated with an increased risk of developing ILD, the presence of anti-Mi2 antibodies typically confers a favorable prognosis, with rare lung involvement. This case report presents a diagnostically challenging instance of a patient with positive anti-Mi2 antibodies who developed rapidly progressive ILD (RP-ILD) versus possible Pneumocystis jiroveci pneumonia (PJP). We present a 74-year-old Caucasian woman with a history of Stage IV adenocarcinoma with brain metastasis, complicated by vasogenic edema, treated with 12 mg of dexamethasone daily. Two weeks later, she developed proximal muscle weakness and was diagnosed with steroid-induced myopathy. Four weeks afterward, she presented with progressive shortness of breath and hypoxia, requiring high-flow nasal cannula and ICU admission. CT imaging revealed new multifocal opacities with perihilar ground-glass opacities. Review of previous investigations showed linear ground-glass opacities in the left lung and a positive anti-Mi2 autoantibody. The patient was started on intravenous steroids and intravenous immunoglobulin (IVIG) with subsequent improvement. On day five of hospitalization, serum beta-D-glucan returned elevated. Due to overlapping features with PJP, trimethoprim/sulfamethoxazole was initiated. The patient improved significantly and was later discharged on room air. Follow-up imaging six months later showed near-complete resolution. This case highlights the diagnostic complexity in critically ill, immunosuppressed patients with acute respiratory failure, where both autoimmune and infectious etiologies, such as PJP, should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.